Physician profile
Barry A Ruht
NPI 1871542621
$1,265.53
in general payments reported to CMS, 2019-2025
15 companies · $31.04 in 2025
The $31.04 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $204 · 2021: $264 · 2022: $356 · 2023: $67.28 · 2024: $42.19 · 2025: $31.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $261.47 | 2019-2025 | Orthovisc, Monovisc |
| Novus Surgical Solutions LLC | $252.98 | 2019-2022 | |
| Horizon Therapeutics Plc | $150.95 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $93.68 | 2020-2021 | |
| Fidia Pharma USA INC. | $90.06 | 2019-2023 | Triluron |
| Ferring Pharmaceuticals INC. | $84.21 | 2019-2022 | |
| Bioventus LLC | $66.83 | 2019-2023 | Supartz Fx Sodium Hyaluronate |
| Pacira Therapeutics, INC. | $59.33 | 2019-2020 | |
| Electronic Waveform Lab, INC. | $48.01 | 2019-2020 | |
| Ibsa Pharma INC. | $36.53 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $33.80 | 2022 | |
| Orthofix Medical, INC. | $29.71 | 2021-2024 | Physio-Stim |
| Alexion Pharmaceuticals, INC. | $26.30 | 2019 | |
| Orthogenrx INC. | $17.43 | 2020 | |
| Avanos Medical | $14.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Ruht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.